Pharma Pricing Under Pressure: U.S. Reforms and Potential Implications for the EU Industry

• Comparative overview of pharmaceutical pricing between the U.S. and Europe
• CMS/Medicare pricing negotiations and potential implications of the proposed Most Favored Nation (MFN) pricing model
• Potential U.S. reform initiatives: price referencing and proposed tariffs on pharmaceuticals
• Potential strategic impacts on the EU pharmaceutical industry, payers, and patients

Who should attend

• Market Access
• Pricing & Reimbursement
• Health Economics
• International Strategy and Business Development

This seminar offers an overview of current transatlantic developments in pharmaceutical pricing. Participants will gain insight into key differences between the U.S. and European pricing structures, with a particular focus on U.S. reforms and their global repercussions. Special attention will be paid to CMS/Medicare negotiation mechanisms, the potential implications of the proposed Most Favored Nation (MFN) pricing model and the emerging threat of U.S. tariffs on pharmaceuticals.

The seminar concludes with an outlook on potential implications for the European pharmaceutical landscape, including potential consequences for manufacturers, payers, and patients.

• Gain early insight into policy shifts that could reshape global pharmaceutical markets.
• Understand the legal and commercial risks posed by U.S. price control initiatives and trade measures.
• Stay informed on how U.S. price negotiations and tariff policies may influence EU pricing strategies and export compliance.